Table 3. The distribution of HBV integration sites, mutational status of selected tumor suppressor genes and numbers of chromosomal aberrations identified in the 25 patients whose samples were assayed using aCGH assay.

Case No.	TP53 status	TP53BP2 (ASPP2)	RB1	CDKN2A	TP73	BRCA1	BRCA2	Aberration Number	HBV integration number
									Tumor	Non-tumor
339C	W/O	gain	loss		partial-gain	gain		537	7	9
348C	LOH			loss				403	0	2
H-53	point mutation+LOH	gain		loss		gain		339	3	0
H-44	W/O		loss	loss	loss		loss	258	0	4
350C	LOH							204	0	2
H-70	point mutation		loss		loss			179	5	6
H-61	LOH	gain	loss	loss			loss	146	1	2
H-42	LOH	gain	loss					130	4	2
H-60	W/O				loss			97	11	8
H-64	W/O	gain				loss		96	6	5
H-68	W/O	loss						74	1	9
H-54	W/O	gain			loss			72	0	0
H-49	W/O				partial-gain			66	0	0
H-57	W/O							14	1	3
351C	LOH							11	2	0
197C	W/O							25	4	7
346C	W/O					loss		136	1	0
414C	W/O	gain			partial-gain			382	0	6
432C	LOH		loss		loss		loss	288	2	10
493C	W/O							126	0	0
508C	point mutation+LOH		loss		loss		loss	336	1	3
509C	W/O							176	2	7
535C	W/O	gain	loss	loss	loss		loss	235	0	2
571C	W/O							357	5	4
585C	point mutation+LOH			loss				204	2	2

W/O = without mutation; Low aberration number = less than 100 chromosomal aberrations; High aberration number = more than 100 chromosomal aberrations.